Immunotech Laboratories Inc
OTC:IMMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Immunotech Laboratories Inc
OTC:IMMB
|
US |
|
S
|
Standard BioTools Inc
F:FLB
|
US |
Intrinsic Value
The intrinsic value of Immunotech Laboratories Inc (IMMB) under the Base Case is 0.00004 USD per share. Compared with the current market price of 0.0002 USD, the stock appears Overvalued by 81% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Immunotech Laboratories Does
Immunotech Laboratories, Inc. is a drug development company. The company is headquartered in Glendale, California and currently employs 4 full-time employees. The company went IPO on 2002-01-07. The firm is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.
- Headquarters
- United States of America US
- Employees
- 4
- IPO date
- Jan 7, 2002
Earnings Waterfall
Immunotech Laboratories Inc
The intrinsic value for Immunotech Laboratories Inc (IMMB) under the Base Case is 0.00004 USD.
Compared with the current market price of 0.0002 USD, the stock appears Overvalued by 81% .